| Autor: |
K. N., Vijayakumar, Bamne, Swati S., Crasta, Johnson, Kumar C., Satish, Bhat, Ramakrishna M., Shuster, Bentley M., Oliver, John W. K., Abbott, Zachary D. |
| Předmět: |
|
| Zdroj: |
Journal of Applied Toxicology; Dec2024, Vol. 44 Issue 12, p1874-1885, 12p |
| Abstrakt: |
The novel genetically modified probiotic Bacillus subtilis ZB423 was assessed in a 90‐day repeated‐dose oral toxicity study adhering to Good Laboratory Practice (GLP) and Organization for Economic Cooperation and Development (OECD) guidelines. Spray‐dried spores at a concentration of 1.1E12 CFU/g were administered at doses of 130, 260, and 519 mg/kg body weight/day correlating to 1.43 × 1011, 2.86 × 1011, and 5.71 × 1011 CFU/kg/day, respectively, by oral gavage to Wistar rats for a period of 90 consecutive days. Results showed no toxicologically relevant findings for B. subtilis ZB423 from measured parameters. The no observed adverse effect level (NOAEL) of B. subtilis ZB423 is 519 mg/kg body weight/day corresponding to 5.71 × 1011 CFU/kg/day for lyophilized B. subtilis ZB423 spores under the test conditions employed. The novel genetically modified probiotic B. subtilis ZB423 was assessed in a 90‐day repeated‐dose oral toxicity study. Results showed no toxicologically relevant findings for B. subtilis ZB423 from measured parameters. The no observed adverse effect level (NOAEL) of the B. subtilis ZB423 is 519 mg/kg body weight/day corresponding to 5.71 × 1011 CFU/kg/day for lyophilized B. subtilis ZB423 spores under the test conditions employed. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text